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THE EFFECT OF PRIMARY AND SECONDARY CIGARETTE SMOKE ON AUDITORY 




Advisor: Carol Silverman, Ph.D., M.P.H. 
Objective: The goal of this paper was to systematically review literature in order to investigate 
the effects of active and passive cigarette smoke on auditory function when assessing outcome 
measures including pure tone audiometry, otoacoustic emissions, high-frequency audiometry, 
and auditory evoked potentials. 
Methods: A comprehensive search using the Medline Complete database was conducted to 
identify relevant studies published after 2005. Inclusion criteria included the use of pure tone 
audiometry, high-frequency audiometry, otoacoustic emissions, and/or auditory evoked 
potentials to examine the effect of primary or secondary cigarette smoke. Studies involving noise 
exposure or other confounding factors were excluded. 
Results: A total of 19 studies were selected for review based on their research design, 
publication date, and inclusion criteria. All included studies achieved a significant negative 
correlation between cigarette smoking and auditory function for both active and passive smokers. 
Additionally, a dose effect was noted as poorer outcomes were achieved as smoking behavior, 




Discussion: Significant effects of smoking on auditory function were noted across outcome 
measures suggesting a negative effect across levels of the auditory system. Effects on auditory 
function were noted even in those who had quit smoking suggesting long term side effects of the 
behavior on auditory function. A dose effect was noted with negative effects increasing across 
groups from never smokers, to passive smokers, to current smokers. The dose effect was further 
stratified within the current smoking group as negative effects increased with an increase in 
smoking behavior.  
Conclusion: Smoking behavior should be avoided due to its effects on auditory function, as well 
as the myriad of other heavily researched deleterious side effects. It would be advantageous to 
include the question of smoking behavior in an audiologic evaluation intake form. This question 
should also include systematic exposure to secondhand smoke. Additionally, smoking cessation 
can be recommended to reduce effects on auditory function.  
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Worldwide, there are roughly 1 billion (967 million) smokers aged 15 years of age and 
older (Ng, Freeman, & Fleming, 2014). Of these 1 billion smokers, 31% are male and 6.1% are 
female (Lisowska, Jochem, Gierlotka, Misiotek, & Scierski, 2017). As a result, 88 million adults 
and children of at least three years of age are exposed to secondhand smoke (SHS) (Centers for 
Disease Control, 2010). By 2025, an estimated 1.5 – 1.9 billion people will be smokers (Shafey, 
Dolwick, & Guindon, 2003). According to the Centers for Disease Control (CDC), smoking 
prevalence is slightly less than 15% in the United States, with 15.8% of all males and 12.2% of 
all females reporting smoking “some days” or “every day.” Of these, 75% report smoking every 
day. In terms of age groups, 10.4% of adults age 18 – 24 years, 16.1% of adults age 25 – 44 
years, 16.5% of those age 45 – 64 years, and 8.2% of those over 65 years, report current smoking 
either “every day” or “some days” (CDC, 2017). Additionally, of those 65 years and older, 80% 
have at least one chronic condition, which smoking often exacerbates (Fried, Freedman, Endres, 
& Wasik, 1997). Hearing loss itself is ranked third among chronic health conditions in adults age 
65 years and older (Collins, 1997). It is a major public health concern with a prevalence of 33% 
in adults 65 or more years of age (Davila et al., 2009).  
Tobacco use is the leading cause of preventable deaths worldwide (World Health 
Organization, 2003). In the United States, cigarette smoking causes 480,000 deaths each year 
and increases the risk of death from all causes across genders. Smokers are at a greater risk for a 
myriad of health conditions such as bacterial respiratory infections, acute and chronic viral 
diseases, oral, laryngeal, esophageal, pancreatic, renal, and bladder cancer, circulatory disease 
such as arteriosclerosis, aortic aneurism, stroke, and multiple other organ disorders. Specifically, 




men by 25 times, and of lung cancer in women by 25.7 times. Smoking also increases both the 
risk and severity of Chronic Obstructive Pulmonary Disease (COPD) with smokers being 12 to 
13 times more likely to die from COPD than non-smokers (U.S. Dept. of Health and Human 
Services, 2010; 2014). Other smoking effects include reduced fertility, bone health, tooth and 
gum health; increased risk of cataracts, age-related macular degeneration, type 2 diabetes, 
rheumatoid arthritis; and general adverse effects including inflammation and decreased immune 
function (U.S. Department of Health and Human Services, 2001; 2010; 2014). Smokers not only 
exhibit poorer vascular and respiratory health, but also present with poorer cognitive health 
included an increased risk for dementia, with many showing reduced cognitive performance later 
in life (Chang, Ho, Wang, Gentleman, & Ng, 2014; Mons, Schottker, Muller, Kliegal, & 
Brenner, 2013).  
Cigarette smoking is the primary method of nicotine intake with each cigarette containing 
9 – 13 mg of nicotine (Kozlowski, Henningfield, & Brigham, 2001). Nicotine is rapidly absorbed 
by nicotinic receptors in the nervous system and can lead to physiologic, cognitive, and sensory 
effects (Stratton, Shetty, Wallace, & Bondurant, 2001). Additionally, cigarette smoke contains 
more than 4500 complex chemicals including carbon monoxide (CO), carbon dioxide, mercury, 
and arsenic (Gopal, Herrington, & Pearce, 2009; Cruickshanks et al., 1998). The effects of such 
toxicity are greatly related to number of cigarettes smoked, age of smoking onset, degree of 
inhalation, and the different characteristics of cigarette brands such as tar and nicotine content 
(Peto, 1986). Smoking simultaneously increases the need for oxygen while decreasing the 
amount of oxygen reaching the bloodstream, thus minimizing oxygen available to vital organs 




system, smoking is related to lower blood oxygen levels, increased blood viscosity, vascular 
obstruction, and possible ototoxicity (Paschoal & Azevedo, 2009).  
Specific to auditory function, the inner ear is dependent on adequate blood supply and 
thus may be susceptible to alterations in blood flow caused by tobacco. These alterations include 
peripheral vascular changes, such as increased blood viscosity and reduced oxygen availability. 
As a result, smoking is known to affect cochlear circulation, inducing vasospasm and 
arteriosclerosis in the cochlear blood vessels. Not only does smoking adversely affect cochlear 
circulation, but also it adversely affects the cardiovascular system; in turn, this effect on the latter 
leads to an increased risk of diabetes, which can result in hearing loss. Nicotine in tobacco smoke 
has a direct ototoxic effect on cochlear hair cells. Carbon monoxide in tobacco smoke can cause 
a rise in carboxyhaemoglobin levels in smokers, which can reduce the passage of oxygen for the 
Organ of Corti. As noted previously, smoking increases the need for oxygen in the human body 
and the rise in carboxyhaemoglobin levels results in a reduction of available oxygen. Even 
exposure to SHS can damage the inner ear due to hypoxemia or direct injury by nicotine or other 
chemicals (Lalwani, Liu, & Weitzman, 2011; Talaat, Metwaly, Khafagy, & Abdelraouf, 2013). 
Some researchers have suggested that smokers who are older than 40 years of age have an 
increased prevalence of hearing loss, reflecting an additive effect of the normal aging process 
and the aforementioned effects of smoking on the cochlea. Age-related degenerative changes can 
also affect the vascular structures of the cochlea, just as tobacco does (Chang, Ryou, Jun, 
Hwang, Song, & Chae 2016; Ferrite & Santana, 2005).  
Nomura, Nakao, and Morimoto (2005) conducted a meta-analysis examining the effect of 
smoking on pure-tone thresholds. In contrast with the current review, those investigators 




limited their search to studies utilizing pure-tone average alone as their outcome measure. Their 
review revealed a positive association between smoking and pure-tone average. Research 
findings reveal significant relative risk for hearing loss from hearing loss in current smokers: 
relative risk was 1.33 (95% CI: 1.24, 1.44) based on cross-sectional studies; 1.97 (95% CI: 1.44, 
2.70) based on cohort studies; and 2.89 (95% CI: 2.26, 3.70) based on case-control studies. 
Furthermore, relative risk also was significant for hearing loss in ex-smokers: relative risk was 
1.17 (95% CI: 1.03, 1.33) based on cross-sectional studies; and 1.83 (95% CI: 1.43, 2.35) based 
on case-control studies. Although the investigators extracted data on age, noise exposure, and 
smoking history, this association was dependent on the adjustment for confounding factors such 
as age, noise exposure, and history of ear disorders. The purpose of this study was to conduct a 
systematic review of studies on smoking and hearing loss which utilized pure tone thresholds in 
the conventional range, ultra high-frequency thresholds, otoacoustic emissions (OAE) and 





The Medline Complete online database was searched. Search filters included peer-
reviewed journals as well as articles published after 2005. The main search terms utilized were 
“smoking,” and “hearing loss.” Supplementary search terms, such as, “cigarettes,” “passive 
smoking,” “smoke exposure,” and “auditory evoked potentials” were utilized to find additional 
studies for inclusion. This initial search yielded a total of 344 studies. As an existing systematic 
review assessed articles prior to 2005, the present review focused on those published in the years 
following 2005.  
Studies were excluded if they involved concurrent effects of smoking and noise exposure 
or if the subjects included infants or children. This resulted in the exclusion of 318 studies. 
Subsequently applied exclusion criteria were animal studies or studies on individuals with 
schizophrenia and/or major depressive disorder or alcoholism; and studies on middle-ear 
pathologies and surgical outcomes resulting in the exclusion of 297 studies.  Two studies 
originally published in the Georgian Medical news were excluded due to ambiguity of writing 
style and reporting of results. These exclusion criteria resulted in the 19 studies evaluated in this 
systematic review. Data extracted from the included studies involved conventional and ultra 












 Of the 19 studies evaluated, 89% (17) employed a descriptive, case-control research 
design, and 11% (2) employed a descriptive design whereby the characteristics of a single group 
of smokers or individuals exposed to secondhand smoke (SHS) are described. The majority of 19 
studies (74%) were based on a sample size of at least 30 (Guney, Genc, Kutlu, & Ilhan, 2009; 
Gupta, Sood, Atreja, & Agarwal, 2008; Kumar, Gulati, Singhal, Hasan, & Khan, 2013; 
Lisowska, Jochem, Gierlotka, Misiotek, & Scierski, 2017; Ohgami Kondo, & Kato, 2011; 
Oliveira & Lima, 2009; Paschoal & Azevedo, 2009; Prabhu, Varma, Dutta, Kumar, & Goyal, 
2017; Ramkissoon & Chambers, 2008; Ramkissoon & Cole, 2011; Sekher, Sinha, & Jha, 2017; 
Sumit et al., 2015), with the remainder (26%) based on a sample size of less than 30 (Gopal, 
Herrington, & Pearce, 2009; Negley, Katbamna, Crumpton, & Lawson, 2007). Of the 14 large-
sample studies, 2 (14%) were population-based. Chang et al. (2016), drew participants from the 
Korea National Health and Nutrition Examination Survey (KNHANES). The KNHANES is an 
ongoing population study that began in 1998, with individuals who participated from 2010 – 
2012 included in the Chang et al. study. Fabry et al. (2011) drew participants from the U.S. 
National Health and Nutrition Examination Survey (NHANES) who completed audiometric 
testing, provided complete smoking and medical histories, and who had a valid recorded serum 
cotinine value.  
 Of the 19 studies, 15 (79%) compared only 2 groups: smokers versus non-smokers; 1 
(5%) involved only current smokers; 1 (5%) included a passive smoking group (those exposed to 
SHS) along with groups of smokers and nonsmokers; 1 (6%) involved only a passive smoking 
group; and 1 (5%) study compared smokers, non-smokers, and those who had quit smoking in 




included past smokers, or those who quit smoking, in the non-smoking group. Of the 19 studies, 
16 (84%) included groups matched for age while the remaining 3 (16%) separated groups into 
older and younger participants.  
 In terms of the quantification of smoke exposure, all studies subjectively assessed smoke 
exposure by self-reported responses to either a single question or multiple questions on smoking 
status. The questionnaires elicited general health information included in medical records or self-
reported basic history involving smoking status, packs/cigarettes per day, frequency of smoking, 
and number of years as a smoker. Ohgami et al. (2011) also employed the Brinkman Index (BI) 
to examine the frequency or degree of smoking in the participants. The BI represents the number 
of cigarettes smoked per day multiplied by the number of years smoking (Brinkman & Coates, 
1963). All the individuals in their non-smoking group had a BI of 0, whereas those in the 
smoking group all were classified as “light-smokers” with BI scores between 12 and 60. One 
study used the Global Initiative for chronic obstructive Lung Disease (GOLD) guidelines to 
diagnosis Chronic Obstructive Pulmonary Disease (COPD) (Gupta et al., 2008). The GOLD 
guidelines outline the key indicators of a COPD diagnosis, including dyspnea that is progressive 
and persistent, chronic cough, chronic sputum production, a history of risk factors, including but 
not limited to genetic factors, tobacco smoke, and occupational dusts or vapors, as well as a 
family history of COPD and/or childhood factors including low birth weight and childhood 
respiratory infections These guidelines also characterize the severity of COPD on a four tier 
scale (ABCD) (GOLD, 2019). 
 Of the 19 total studies, only 5 (26%) additionally used objective measures of smoke 
exposure (Fabry et al., 2011; Ramkissoon & Cole, 2011). Gopal et al. (2009) measured breath 




breath CO monitor, used to measure the concentration of CO in the individual’s breath, allows 
for the quick and accurate assessment of the presence of CO. Fabry et al. used serum cotinine 
levels to determine the level of secondhand smoke exposure. Cotinine, a biomarker of exposure 
to tobacco in both active and passive smokers, or those exposed to tobacco smoke, is the primary 
metabolite of nicotine (Benowitz, 1996). As the lower limit of detection of serum cotinine is 0.50 
ng/mL and the suggested level indicating current smokers is 3 ng/mL or above, only individuals 
with levels within this range (0.50 – 3 ng/mL) were included. Ramkissoon and Cole  also utilized 
cotinine levels to determine smoking status. Additionally, they tested the urine of participants for 
the presence of this biomarker, as well as for the presence of nicotine. The self-reports of 
smoking status and the biochemical results were in 100% agreement. Mobascher et al. (2009) 
utilized carboxyhemoglobin (COHb), a complex of carbon monoxide that forms in red blood 
cells when carbon monoxide is inhaled, as an objective measure of smoke exposure 
(Thaniyavarn & Eiger, 2014).  
 Outcome measures included conventional pure-tone thresholds (250 – 8,000 Hz), ultra 
high-frequency thresholds, OAEs, and latencies and amplitudes of AEPs. Of the 19 studies, the 
majority 14 (74%) assessed conventional pure-tone thresholds; 6 (32%) evaluated extended or 
ultra high-frequency pure-tone thresholds; 6 (32%) examined OAEs; and 6 (32%) evaluated the 
AEPs. The percentages total more than 100% as some studies evaluated more than one type of 
outcome measure. Tables 1 through 4 shows the characteristics of the studies on effects of 
smoking on conventional pure-tone thresholds, ultra high-frequency pure-tone thresholds, OAEs, 














Chang et al 
(2016) 
12,935 South Korean 
individuals aged 19+ 
yrsa: current smoking 
group (n= 3,374), 
passive smoking group 
(n= 2,792), non-
smoking group (n= 
6,769) 
Smoking group - 
currently smoke; 
passive smoking 
group - exposed 
to cigarette fumes 
daily at home 
and/or work; non-
smoking group - 
never smoked and 
never exposed to 
cigarettes 
Presence of unilateral 
hearing impairment 
Chi-square (χ2 ) 
testing, odds ratio 
with 95% CI 
(adjustments for 












Fabry et al 
(2011) 
5147 Subject population 
aged 20 - 69 yrs who 
were not current 
smokers but SHS 
exposed 
Secondhand 
smoke expose - 
serum contine 
level at or above 
0.050 ng/mL 
Current smokers 
(based upon Qb and 





Gopal et al 
(2009) 
16 Adult male smokers 
with no hxc of HL and 
hx of smoking of 4 yrs 
on average and a mean 
use of 17 cigarettes per 
day aged 18 – 24 




out via otoscopic 
examination 
Linear regression 
and effect size 
















Kumar et al 
(2013) 
148 108 male smokers aged 
20 - 60 yrs (mean 
age=37 yrs) age-
matched non-smokers 




Hx of ototoxic drugs, 
diabetes, hypertension, 
hearing loss, severe or 
frequent ear 
infections, ear surgery, 
head injury, noise 







84 41 non-smokers (mean 
age=33 yrs) and 43 
smokers (mean age=35 
yrs) aged 25-45. Total 
of 46 females and 38 
males in Poland. 
Smoking for 7+ 
yrs and 15+ 
cigarettes/day 





hearing loss, noise 
exposure, ototoxic 
drugs, head injury, 
family history of 







BMIe, and other acute 
























Negley et al 
(2007) 
24 12 smokers and 12 non-
smokers aged 20-30 yrs 
In smokers: hx of 
5-8 years of 
smoking 





3 factor ANOVAi Descriptive  
case control 
Ohgami et al 
(2011) 
51 Smoking and non-
smoking males aged 21 
- 23 yrs 




number of yrs 
smoked 








60 30 male smokers aged 
18 -40 yrs (mean 
age=31 ± 6 yrs); 30 
male age-matched non-
smokers (mean age=28 
± 6 yrs) 
Smokers were 
active smokers 
for 5+ yrs 
Hx of ear disorders, 
tinnitus, dizziness, 
hearing loss, prior ear 
surgery, otoscopic 
alterations, work-
related noise exposure, 
hypertension, diabetes; 
neurologic disease; 
PTT > 25 dB HL at 









144 72 smokers and 72 non-
smokers paired by 








presence of inner or 
middle ear disorders, 
metabolic disordrs, 
hormonal disorders, or 
Student t-test, 
Mann-Whitney U 
test, two ratio 
equality tests, and 


















Prabhu et al 
(2017) 
50 25 male smokers and 
25 male non-smokers 
aged 18-402 yrs in India 
Current smokers 
who have smoked 
for 1+ yr; PTTs ≤ 
25 dB HL (.25l - 
6k Hz) 
Otological hx of noise 
exposure, ototoxic 
drugs, diabetes, family 














170 61 males, 109 female; 
98 non-smokers and 72 
smokers; younger 
group n= 80, age 19 - 
30 (mean age 24±3.9) 
and older group n=90, 
age 45+ mean age 
62±9.3); non-smokers 
included those who quit 
smoking 3+ years prior 





smokers - never 
smoked or quit at 
least 3 years prior 
Poor overall health, 
alcohol or drug 
dependency, mental 











Rogha et al. 
(2015)  
32 Men aged 20 - 60; 
smoking group and 
non-smoking group 
matched for age and 
gender 
 No history of ototoxic 






exposure, outer and/or 



















Sekher et al 
(2017) 
120 60 smokers and 60 non-




otitis media and other 
middle and internal 
ear pathology; hx of 
ototoxic drugs, 
working in a noisy 
environment, 
congenital anomalies, 
and other systemic 
diseases such as 
diabetes and viral 
infection causing 







Sumit et al 
(2015) 
184 90 male smokers (mean 
age 39 ±12 yrs) and 94 
male non-smokers 
(mean age 36 ± 12 yrs) 
aged 18-60 yrs in 
Bagladesh; groups did 
not differ on mean age 
or BMI 
Age 18 - 60 yrs Hx of alcohol drinking 
habit, use of portable 
music player with 
earphone, middle-ear 









dCentral nervous system 
eBasal mass index 
fClick evoked otoacoustic emissions 
gPure-tone threshold 
hDistortion product otoacoustic emissions 
iAnalysis of variance 
jMultivariate analysis of variance 
kUltra high frequency 
















Lisowska et al 
(2017) 
84 41 non-smokers (mean 
age=33 yrs) and 43 
smokers (mean age=35 
yrsa) aged 25-45. Total 
of 46 females and 38 
males in Poland. 
Smoking for 7+ yrs 
and 15+ 
cigarettes/day 
Hxb of audiological 
impairment, abnormal 
otoscopic examination, ear 
problems, conductive 
hearing loss, noise 
exposure, ototoxic drugs, 
head injury, family history 
of hearing loss; current 




disorders, abnormal BMId, 











Negley et al 
(2007) 
24 12 smokers and 12 non-
smokers aged 20-30 yrs 
In smokers: hx of 
5-8 yrs of smoking 
Noise exposure or ear 
diseases, abnormal 
middle-ear pathology 
based on tympanometric 
screening 
3 factor ANOVAh, Descriptive  
case control 
Ohgami et al 
(2011)  
51 Smoking and non-
smoking males aged 21 - 
23 yrs 




number of yrs 
smoked 
NA Mann-Whitney U 



















60 30 male smokers aged 
18 -40 yrs (mean age=31 
± 6 yrs); 30 male age-
matched non-smokers 
(mean age=28 ± 6 yrs) 
Smokers were 
active smokers for 
5+ yrs 
Hx of ear disorders, 
tinnitus, dizziness, hearing 





disease; PTT > 25 dB HL 
at any 1+ frequency; 






144 72 smokers and 72 non-
smokers paired by 
gender and age (20 - 31  
yrs) 





Former smokers; presence 
of inner or middle ear 
disorders, metabolic 
disordrs, hormonal 
disorders, or noise-induced 
or drug-induced HL 
Student t-test, 
Mann-Whitney U 
test, two ratio 
equality tests, and 
the Spearman test 
Descriptive 
case control 
Prabhu et al 
(2017) 
50 25 male smokers and 25 
male non-smokers aged 
18-40 yrs in India 
Current smokers 
who have smoked 
for 1+ yr; PTTs ≤ 
25 dB HL (.25l - 6k 
Hz) 
Otological hx of noise 
exposure, ototoxic drugs, 
diabetes, family hx of 










Rogha et al. 
(2015) 
32 Men aged 20 - 60; 
smoking group and non-
smoking group matched 
for age and gender 







exposure, outer and/or 
middle ear disease, 
unilateral or conductive 
hearing loss 















Sumit et al 
(2015) 
184 90 male smokers (mean 
age 39 ±12 yrs) and 94 
male non-smokers 
(mean age 36 ± 12 yrs) 
aged 18-60 yrs in 
Bagladesh; groups did 
not differ on mean age 
or BMI 
Age 18 - 60 years Hx of alcohol drinking 
habit, use of portable 
music player with 
earphone, middle-ear 







cCentral nervous system 
dBasal mass index 
eClick evoked otoacoustic emissions 
fPure-tone threshold 
gDistortion product otoacoustic emissions 
hAnalysis of variance 
iMultivariate analysis of variance 















Gopal et al 
(2009) 
16 Adult male smokers with 
no history of HL and hxb 
of smoking of 4 yrsa on 
average and a mean use 
of 17 cigarettes per day 
aged 18 - 24 
Current smokers Hearing loss and 
outer/middle ear 
problems, peripheral 








Lisowska et al 
(2017) 
84 41 non-smokers (mean 
age=33 yrs) and 43 
smokers (mean age=35 
yrs) aged 25-45. Total of 
46 females and 38 males 
in Poland. 
Smoking for 7+ yrs 
and 15+ 
cigarettes/day 




conductive hearing loss, 
noise exposure, ototoxic 
drugs, head injury, 
family history of hearing 





abnormal BMId, and 








and DPOAEg).  
Descriptive 
case control 
Negley et al 
(2007) 
24 12 smokers and 12 non-
smokers aged 20-30 yrs 
In smokers: hx of 
5-8 years of 
smoking 
Noise exposure or ear 
diseases, abnormal 
middle-ear pathology 
based on tympanometric 
screening 


















144 72 smokers and 72 non-
smokers paired by gender 
and age (20 - 31  yrs) 






presence of inner or 
middle ear disorders, 
metabolic disordrs, 





test, two ratio 
equality tests, and 
the Spearman test 
Descriptive 
case control 
Prabhu et al 
(2017) 
50 25 male smokers and 25 
male non-smokers aged 
18-40 yrs in India 
Current smokers 
who have smoked 
for 1+ yr; PTT ≤ 25 
dB HL (.25l - 6k 
Hz) 
Otological hx of noise 
exposure, ototoxic 
drugs, diabetes, family 










Rogha et al. 
(2015) 
32 Men aged 20 - 60; 
smoking group and non-
smoking group matched 
for age and gender 
 No history of ototoxic 






exposure, outer and/or 
middle ear disease, 
unilateral or conductive 
hearing loss 




cCentral nervous system 
dBasal mass index 
eClick evoked otoacoustic emissions 
fPure-tone threshold 
gDistortion product otoacoustic emissions 
hAnalysis of variance 
iMultivariate analysis of variance 

















Gopal et al 
(2009) 
16 Adult male smokers with 
no history of HL and hxb 
of smoking of 4 yrsa on 
average and a mean use 
of 17 cigarettes per day 
aged 18 - 242 
Current smokers Hearing loss and outer/middle 
ear problems, peripheral 
abnormalities ruled out via 
otoscopic examination 
Linear regression 




Guney et al 
(2009) 
64 32 male and female 
smokers and 32 age, 
gender and education 
level matched healthy 




by inhalation for 
12+ yrs, all 
participants right-
handed 
Lifetime hx of major medical 
disorder (neurological, hepatic, 
or cardiovascular); head injury 
with loss of consciousness; 
seizures; sedative, barbiturate, 
alocohol or cocaine abuse or 
dependence; uncorrected 
auditory or visual impairment; 
current psycoactive medication 
use; women currently in the 
menstration phase of the 
menstrual cycle 
Independent 







Gupta et al 
(2008) 
80 40 male smokers with 
stable COPDi with a 
duration of symptoms of 
5+ yrs and 40 male aged-
matched healthy controls 
40+ yrs 
Smokers: COPD 





course of disease 
with regular follow 
up in the preceding 
yr, and no 
hospitilizations 
related to COPD in 
the prior 6 months 
Smokers: +clinical evidence of 
neurological deficit or 
neuropathy, concomitant 
diabetes, alcoholism, uremia, 
cystic fibrosis, sarcoidosis, 
leprosy, malignancy, hereditary 
disorders involving peripheral 
nerves; hx of neurotoxic drug 
use or traumatic lesion to the 
brainstem. Controls: hx of 






















Jawinski et al 
(2016) 
1739 Current (n=136), ex- 
(n=272), and never 
smokers (n=468) age 40 - 
79 yrs; participants 
matched on sex, age, 




those with no 6 month 
history of 5+ cigarettes 
per week 
Individuals from an 
existing study with 
sufficient EEGe 
assessment; data on 
socioeconomic 
status, tobacco use, 




Current psychiatric disorder or 
intake of psychotropic 
medication; hx of major 
neurological disorder, or being 
a cigar, cigarillo, stogie, or pipe 
smoker; moderate or worse HL 
(>55 dB HL) 
Repeated measures 
ANCOVAf with sex 







1318 German light smokers 
(n=325; mean age=36 
yrs), heavy smokers 
(n=271; mean age=41 
yrs), or never smokers 
(n=722; mean age=35 
yrs) aged 18-65 yrs 
(mean age=37 yrs) 
Aged 18-65 yrs, 
current smoker with 
7+ cigarettes per 
week/one per day; 
paticipant's 
grandparents born 
in germany; fluent 
German speakers 
Former smokers, alcohol or 
substance abuse in the past 6 
months; psychiatric diagnosis 
in the past 6 months; non-
german origin; non-fluent in 
German; serious impairments 
of hearing or vision; pregnany; 
CNSg-related medication within 
6 months; neurological illness 
ANCOVA with 
P300 GFPh as 
dependent variable 
and smoking status, 
gender, and study 
site as independent 
variable. Age, years 
of education, 








40 Younger non-smokers 
(n=10), younger smokers 
(n=10), mean age=25 yrs; 
older non-smokers 
(n=10) and older smokers 
(n=10), mean age= 61 
yrs) ; included past 
smokers in non-smoking 
groups 
Younger group: age 
19-30 yrs; Older 
group; age 55-81 






Alcohol or drug dependency, 
mental illness, neurological 
disease, significant HL, MLRc 
contaminated by post-auricular 
muscle reflex, mismatched 
between urine analysis and self 












dMultivariate analysis of variance 
eElectroencephalogram 
fAnalysis of covariance 
gCentral Nervous System 
hGlobal Field Potential 








Pure-Tone Thresholds  
Conventional audiometric range 
 Fourteen of the 19 studies (74%) utilized conventional pure-tone thresholds as an 
outcome measure (Chang et al., 2016; Fabry et al., 2011; Gopal et al., 2009; Kumar et al., 2013; 
Lisowska et al., 2017; Negley et al., 2007; Ohgami et al., 2011; Oliveira & Lima, 2009; Paschoal 
& Azevedo, 2009; Prabhu et al., 2017; Ramikissoon & Cole, 2011; Sekher et al., 2017; Sumit et 
al., 2015). Inspection of Table 1 reveals that the studies were performed on current smokers, 
individuals who have either never smoked or not smoked in five or more years, as well as 
passive smokers, or those who do not actively smoke, but are exposed to smoke in some way. 
Table 5 shows the outcome measures, procedures, and findings of the the studies on effects of 
smoking on the conventional pure-tone thresholds. 
 As seen from inspection of Table 5, no statistically significant differences in conventional 
pure-tone thresholds between smokers and non-smokers were seen in in 3 of the 14 studies 
(21%) (Lisowska et al., 2017; Ohgami et al. 2011; Ramkissoon & Cole, 2011). Ramkissoon and 
Cole found no significant difference in conventional pure-tone thresholds between smokers and 
non-smokers when examining the presence or absence of mild (PTA > 25 dB dB HL), moderate 
(PTA > 40 dB dB HL), severe (PTA > 60 dB HL) hearing loss, or reduced word-recognition 
score (WRS < 88%). Ohgami et al. found no significant differences in mean thresholds (1 – 8k 
Hz) between smokers and non-smokers. Gopal et al. (2009) found that conventional pure-tone 
thresholds (3-frequency PTA at .5, 1, and 2k Hz) did not account for variance in CO levels of 
participants. Lisowska et al. found worse pure-tone thresholds in smokers than in non-smokers at 
all frequencies tested (.25 – 20k Hz), but these results failed to reach significance. Although no 





Cole did find that both younger participants, when compared to older participants as well as 
smokers compared to non-smokers overestimated their self-reported hearing impairment.  
Inspection of Table 5 also reveals that in the remaining 11 of the 14 (79%) studies,  the 
pure-tone thresholds were significantly poorer in smokers than in non-smokers and passive 
smokers. Although the pure-tone thresholds were worse in smokers than in non-smokers and 
passive smokers, the thresholds did not always fall outside the normative hearing range (25 dB 
HL). In several studies, smokers had significantly poorer mean thresholds across the frequency 
range (.25 – 8k Hz) than non-smokers (Kumar et al., 2013; Negley et al, 2015; Oliveira & Lima, 
2009; Prabhu et al., 2017). Kumar et al found that the severity of hearing loss (based on the 4-
frequency PTA across .5, 1, 2, and 4k Hz) increased significantly as the duration of smoking and 
number of cigarettes smoked increase. Negley et al., who analyzed the thresholds at .25 to 8k Hz 
data using three-factor ANOVAs (subject group x ear side x hearing level),  found that the mean 
hearing thresholds of smokers were significantly poorer than those for non-smokers, with 
maximal effects noted at 6 and 10k Hz. . Oliveira and Lima found significantly higher mean 
thresholds at .25 – 6k Hz in smokers (mean = 11.4 dB HL) compared with non-smokers (mean = 
9.4 dB HL). Although Prabhu et al. primarily examined the pure-tone thresholds at the ultra high 
frequencies, significant differences were noted at 8k Hz with smokers having a poorer mean 
threshold than non-smokers. Although exact valus were not reported, based on inspection of the 
figures, the mean pure-tone threshold at 8k Hz was estimated to be 26 dB HL for smokers and 12 
dB HL for non-smokers. Kumar et al., who examined the 4-frequency PTA (based on .5, 1, 2, 
and 4k Hz), found that the prevalence of hearing impairment was higher in smokers (66%) than 
non-smokers (15%). Sekher et al. (2017), reported on the prevalence of sensorineural hearing 





smokers. They observed significantly higher prevalence of sensorineural hearing loss in smokers 
(48%) than in non-smokers (22%).   
Note from Table 5 that in terms of population-based studies, Chang et al. (2016) found 
statistically significant differences in the prevalence of hearing loss between smokers and non-
smokers across age groups. They also noted significant differences in speech (5-frequency PTA) 
and high frequency PTA (3-frequency). Specifically, smoking prevalence was significantly 
related to speech frequency hearing loss (thresholds of ≥ 25 dB HL at .5, 1, 2, 3, 4k Hz) in 
participants aged 40 – 69 years, as well as to high frequency-hearing loss (present if thresholds ≥ 
25 dB HL at 3, 4, and 6k Hz) in participants aged 30-79 years. Current smokers also had a higher 
prevalence of hearing loss overall compared to both passive and non-smokers in the 40 – 60 year 
age range. After adjusting to age, sex, and noise exposure, the mean speech-frequency PTA was 
significantly higher, by 2.5 dB HL (± .33 dB ) in smokers than non-smokers; it was also 
significantly higher by 1.6 dB HL (± .33 dB) in smokers than passive smokers Additionally, 
passive smokers exhibited a higher prevalence of hearing impairment than non-smokers across 
all age groups, although this finding failed to reach significance in any age group. The passive 
smoking group exhibited significantly poorer mean speech frequency PTA (2.41 dB HL ± .47 
dB) than non-smokers (1.2 dB HL ± .34 dB). 
Table 5 further shows that Fabry et al. (2011) found a significant correlation between 
SHS exposure and the presence of low-mid frequency hearing loss (PTA > 25 dB HL based on 
.5, 1, and 2k Hz) and a significant correlation between former smoking behavior and the 
presence of high- frequency hearing loss exceeding 25 dB HL (4-frequency PTA based on 3, 4, 





Table 5 shows that in one study, although a significant difference in pure-tone threshold 
occurred at just a single frequency (8000 Hz) in the left ear between smokers (mean of 4.5 dB 
HL) and non-smokers (mean of 3.3 dB HL), significantly more smokers than nonsmokers 
presented with tinnitus, and smokers with tinnitus had poorer pure-tone thresholds (.25 – 6k Hz) 
than smokers without tinnitus (Paschoal & Azevedo, 2009). Similarly, Rogha et al. (2015) found 
poorer mean thresholds at 2000 and 8000 Hz in smokers compared with non-smokers. Based on 
inspection of the figures, the estimated mean pure-tone threshold at 2000 Hz was 8 dB HL in 
smokers and 3 dB HL in non-smokers; at 8000 Hz, the estimated mean pure-tone threshold was 






Smoke-Exposure and Outcome Measure, Procedures, and Pure-Tone Threshold Results 




Description of Outcome 
Measure 
Procedure Results 
Chang et al 
(2016) 
12,935 Qa Smoking status Estimated prevalence of 
both speech frequency 
hearing impairment 
(present if thresholds of 
≥25 dB HL at .5, 1, 2, 3, 
4k Hz) and high frequency 
hearing impairment 
(present if thresholds ≥ 25 
dB HL at 3, 4, and 6k Hz) 
according to smoking 
status and stratified by age 
group 
PTTb testing done 
in soundproof 
booth inside 





Smoking related to speech 
frequency bilateral HL in age 
40 - 69 - Current smoking 
group higher prevalance of HL 
than passive or non-smoking 
group in 40 - 60 age groups 
(ORc of 1.39 for smokers); high 
frequency HL in age 30 - 79 - 
current smoking group higher 
prevalance of HL than passive 
or non-smokers (OR of 1.42 for 
smokers); Current smokers had 
high PTAd thresholds than non-
smokers and passive 
smokers***; passive smokers 
had higher PTA thresholds than 
non-smokers*** 
Fabry et al 
(2011)  
5147 Q and serum 
cotinine 
levels 
Smoking status Prevalence of low-mid 
frequency HL (PTA > 25 
dB HL at .5, 1, and 2k Hz) 
and high frequency HL 
(PTA at 3, 4, 6, 8k Hz > 
25 dB HL) 
Measured at .5, 1, 
2, 3, 4, 6, 8k Hz 
(low-mid = .5, 1, 
2k Hz; high = 3, 
4, 6, 8k Hz) 
Correlation between 
secondhand smoke exposure 
and low/mid frequency HL** 
and for high frequency HL for 
former smokers*** 
Gopal et al 
(2009) 
16 Q and breath 
COe 
Breath CO levels PTT (.25 - 8k Hz), pure 
tone average 500, 1000, 
and 2000 Hz; ARTf 
measured ipsilaterally and 
contralaterally; ABRg 
latency and amplitude of 
wave V; TEOAEh 
measured at 1, 1.4, 2, 2.8, 
PTT performed 




at intensity levels 












Description of Outcome 
Measure 
Procedure Results 
and 4k Hz; DPOAEj 
measured at 1, 1.4, 2, 2.8, 
and 4k Hz; MLRk  peak 
latency and amplitude of 
Na and Pa 
Kumar et al 
(2013) 
148 Q Smoking status Presence of HL defined as 
PTA (.5 - 4k Hz) >25 dB 
in the worse ear. Severity 
classified as mild (>25 and 
≤ 40 dB), moderate (>40 ≤ 
60 dB) and severe (>60 
dB) 
PTT (.5k-6kHz) Significantly higher PTT 
overall in smoking group*; 
severity significantly correlate 
with # cigarettes smoked and 
duration of smoking* 
Lisowska et al 
(2017) 
84 Q Smoking status PTT and HFAl mean 
thresholds at each 
frequency, presence or 
absence of CEOAEm, 
SOAEn, and DPOAE for 
non-smokers vs smokers, 
female smokers vs female 
non-smokers, male 
smokers vs male non-
smokers, female non-
smokers vs male non-
smokers, female smokers 
vs. male smokers 












DPOAE (SNR > 
3 dB) 
Higher PTT in smokers - NS 
Negley et al 
(2007) 
24 Q Smoking status PTT - .25-8k Hz; HFA - 
10-20k Hz; DPOAE - 2-8k 
Hz 
PTT at 0.25-














Description of Outcome 
Measure 
Procedure Results 
Ohgami et al 
(2011) 
51 Q Smoking status re 
BI 
Average thresholds at 1 - 
12k Hz of smoking and 
non-smoking group 
PTT (1k-12kHz) PTT poorer at 12k Hz in 
smokers*, no differences in 




60 Q Smoking status Mean thresholds in low 
frequency (.25 - 8k Hz) 
range and high frequency 
(9 - 18k Hz) 
PTT .25, .5, 1, 2, 
4, 6, 8k Hz; HFA 
9, 10, 11.2, 12.5, 
14, 16, 18k Hz 
Significantly higher PTT 





144 Q Smoking status Occurrence of tinnitus, 
PTT at .25 - 8k Hz, HFA 
at 10000, 12500, 14000, 
and 16000 Hz, TEOAE 







Worse thresholds for those 
with tinnitus, than those 
without***, worse PTT 
between .25 - 6K Hz in 
smokersNS, and 8000Hz left 
ear* (median of 5 in smokers 
and 2.5 in non-smokers) 
Prabhu et al 
(2017) 
50 Q Smoking status HFA thresholds at 8, 9, 
10.225, 12.5, and 16k Hz. 
DPOAE amplitude at 8, 9, 









Poorer PTT smokers**. 
Ramkissoon 
& Cole (2011) 
170 Subject 
report and 





Smoking status Presence or absence of 
mild (PTA > 25 dB), 
moderate (PTA > 40 dB), 
severe (PTA > 60 dB) and 





.25, .5, 1, 2, 4, 6, 














Description of Outcome 
Measure 
Procedure Results 
Rogha et al. 
(2015) 
32 Q Smoking status Mean thresholds at .25 - 
16k Hz;  Abnormal results 
for DPOAE/TEOAE 
considered <6 at 1 000, 
2000, 4000, and 6000 Hz 
Pure tone testing 






Higher thresholds at 2000 and 
8000 Hz in smokers compared 
to non-smokers *** 
Sekher et al 
(2017) 
120 Q Smoking status Presence or absence of 
mild, moderate, or severe 
SNHLq 
 Prevalence of SNHL higher in 
smokers 
Sumit et al 
(2015) 
184 Q Smoking status Presence of low/mid 
frequency HL if PTA of 1 
and 4k Hz exceeded 20 
dB, and high frequency 
HL if PTA at 8 and 12k 
Hz exceeded 40 dB 
PTT (1k 4k, 8k, 
12kHz) measured 
in soundproof 
booth using iPod 
with headphones 
Smoking related to 
significantly worse PTT at 8 
and 12k Hz*; PTT signficantly 
worse in those who smoked >5 
years than those who smoked 1 
- 5 years at 12k Hz***; 
Prevalence of HL was higher in 
smokers of both age groups*; 
Controlling for age and BMI, 
smoking increases liklihood of 
HL 4.9, 4.74, 5.04, and 2.85 
times for 12, 8, 4, and 1k Hz, 
respectively*** 
aQuestionnaire  
bPure Tone Threshold 
cOdd’s Ratio 
dPure Tone Average 
eCarbon Monoxide 
fAcoustic Reflex Threshold 
gAuditory Brainstem Response 
hTransient Evoked Otoacoustic Emissions 
iNon-significant  
jDistortion Product Otoacoustic Emissions 
kMiddle Latency Responses 
l High Frequency Audiometry 
mClick Evoked Otoacoustic Emissions 
nSpontaneous Otoacoustic Emissions 
oTransient Evoked Otoacoustics Emissions 
pWord Recognition Score  














Extended high-frequency pure-tone thresholds  
 Extended high-frequency pure-tone thresholds (i.e., at frequencies above 8000 Hz) were 
assessed as an outcome measure in 8 of the 19 studies, (42%) (Lisowska et al., 2017; Negley et 
al., 2007; Ohgami et al., 2011; Oliveira & Lima, 2009; Paschoal & Azevedo, 2009; Prabhu et al., 
2017; Rogha et al., 2015; Sumit et al., 2015). Table 6 shows the outcome measures, procedures, 
and findings of the studies on effects of smoking on the extended high-frequency pure-tone 
thresholds. In 2 of these 8 studies (25%), however, the only extended high-frequencies examined 
were 10 – 12kHz, and these frequencies were included within the conventional audiometric 
frequency range (Ohgami et al.; Sumit et al). Although no significant differences between 
smokers and non-smokers were found in 2 studies (Negley et al.; Rogha et al.), significant 
differences in extended high-frequency thresholds between smokers and non-smokers were 
obtained in the remaining 4 (80%) of the studies assessing ultra high frequencies separate from 
the conventional pure tone range. In three of these studies, significantly worse thresholds at all 
frequencies (10 – 16k Hz) were obtained in smokers compared with non-smokers (Lisowska et 
al.; Oliveira & Lima; Prabhu et al.). Paschoal and Azevedo, on the other hand, found 
significantly worse high-frequency thresholds in smokers than in nonsmokers at only 12,000 and 
14,000 Hz; at 12k Hz. They reported that the mean threshold was 31 dB HL in smokers versus 
21 dB HL in non-smokers; at 14k Hz, the mean threshold was 38 dB HL in smokers versus 28 
dB HL in non-smokers.  
 Inspection of Table 6 shows that Sumit et al. (2015), examining only 10 – 12k Hz in 
terms of extended high-frequency pure-tone thresholds, reported that current smokers with a 




than current smokers with a history of smoking for only 1 – 5 years. This finding is suggestive of 
a dose effect, or an increase in hearing thresholds with increases in years of smoking. Ohgami et 
al. (2011) found poorer mean pure-tone thresholds at all frequencies across the frequency range 
from .25 to 12k Hz in smokers compared to non-smokers. Significant differences, however, in 
mean pure-tone threshold between smokers (estimated mean of 37 dB SPL, based on inspection 
of the figure) and non-smokers (estimated mean of 29 dB SPL, based on inspection of the figure) 





Smoke-Exposure and Outcome Measure, Procedures, and Ultra High-Frequency Pure-Tone Threshold Results 








Description of Outcome 
Measure 
Procedure Results 
Lisowska et al 
(2017) 




PTT and HFA mean 
thresholds at each 
frequency, presence or 
absence of COAE, 
SOAE, and DPOAE for 
non-smokers vs smokers, 
female smokers vs female 
non-smokers, male 
smokers vs male non-
smokers, female non-
smokers vs male non-
smokers, female smokers 
vs. male smokers 









(similar to COAE 
- unreported), 
DPOAE (SNR > 
3 dB) 
Higher high 
frequency PTT in 
smokersNS 
Negley et al 
(2007) 
24 Q Smoking status PTT & HFA 
(subject group x 
ear side x 
hearing level as 
a function of test 
frequency), 
DPOAE (subject 
group x ear side 
x test frequency 




PTT - .25-8k Hz; HFA - 
10-20k Hz; DPOAE - 2-
8k Hz 
PTT at 0.25-





Ohgami et al 
(2011) 
51 Q Smoking status 
re: BIs 
PTT Average thresholds at 1 - 
12k Hz of smoking and 
non-smoking group 
PTT (1k-12kHz) PTT poorer at 12k 



















from 1 - 8kHz 
Oliveira & 
Lima (2009) 
60 Q Smoking status PTT, HFA Mean thresholds in low 
frequency (.25 - 8k Hz) 
range and high frequency 
(9 - 18k Hz) 
PTT .25, .5, 1, 2, 
4, 6, 8k Hz; HFA 
9, 10, 11.2, 12.5, 
14, 16, 18k Hz 
Significantly higher 
PTT overall (RE & 





144 Q Smoking status PTT, HFA, 
TEOAEo 
Occurrence of tinnitus, 
PTT at .25 - 8k Hz, HFA 
at 10000, 12500, 14000, 
and 16000 Hz, TEOAE 








frequency PTT at 
12000 and 14000 
Hz in smokers 
(median of 20 in 
non-smokers and 
30 in smokers)*** 
Prabhu et al 
(2017) 
50 Q Smoking status PTT, HFA, 
DPOAE 
HFA thresholds at 8, 9, 
10.225, 12.5, and 16k Hz. 
DPOAE amplitude at 8, 

















per day*, and 
frequency of 
smoking* 
Rogha et al. 
(2015) 
32 Q Smoking status PTT, DPOAE, 
TEOAE, HFA 
Mean thresholds at .25 - 
16k Hz;  Abnormal 
results for 
DPOAE/TEOAE 
considered <6 at 1 000, 
2000, 4000, and 6000 Hz 
Pure tone testing 




















Description of Outcome 
Measure 
Procedure Results 
Sumit et al 
(2015) 
184 Q Smoking status PTT Presence of low/mid 
frequency HL if PTA of 1 
and 4k Hz exceeded 20 
dB, and high frequency 
HL if PTA at 8 and 12k 
Hz exceeded 40 dB 
PTT (1k 4k, 8k, 
12kHz) measured 
in soundproof 
booth using iPod 
with headphones 
Smoking related to 
significantly worse 
PTT 12k Hz*; PTT 
signficantly worse 
in those who 
smoked >5 years 
than those who 
smoked 1 - 5 years 
at 12k Hz***;  
Controlling for age 
and BMI, smoking 
increases liklihood 
of HL 4.9, 4.74, 
5.04, and 2.85 
times for 12, 8, 4, 
and 1k Hz, 
respectively*** 
aQuestionnaire  
bPure Tone Threshold 
cOdd’s Ratio 
dPure Tone Average 
eCarbon Monoxide 
fAcoustic Reflex Threshold 
gAuditory Brainstem Response 
hTransient Evoked Otoacoustic Emissions 
iNon-significant  
jDistortion Product Otoacoustic Emissions 
kMiddle Latency Responses 
l High Frequency Audiometry 
mClick Evoked Otoacoustic Emissions 
nSpontaneous Otoacoustic Emissions 
oTransient Evoked Otoacoustics Emissions 
pWord Recognition Score  
qSensorineural hearing loss 











Otoacoustic Emissions  
 Six of the 19 (32%) studies utilized OAEs, such as transient evoked otoacoustic 
emissions (TEOAEs), distortion product otoacoustic emissions (DPOAEs), click-evoked 
otoacoustic emissions (CEOAEs), and spontaneous otoacoustic emissions (SOAEs), as an 
outcome measure (Gopal et al., 2009; Lisowska et al., 2017; Negley et al., 2007; Paschoal & 
Lima, 2009; Prabhu et al., 2017; Rogha et al., 2015). Table 7 shows the outcome measures, 
procedures, and findings of the the studies on effects of smoking on OAEs. As seen from Table 
7, all studies employed a questionnaire as an indicator of smoke exposure. Only one study 
involved an objective indicator of smoke exposure; in that study the objective indicator was 
breath CO levels (Gopal et al.).   
 Inspection of Table 7 reveals that Prabhu et al. (2017) as well as Negley et al. (2007) 
obtained significantly lower mean DPOAE amplitude levels in smokers than in non-smokers at 8 
– 16k Hz and at 2 – 8k Hz, respectively. Negley et al. observed this finding at both high (70 dB 
SPL) and moderate (65 and 50 dB SPL) intensities. Lisowska et al. (2017) also found 
significantly lower DPOAE amplitudes in smokers than in nonsmokers, but only at f2 = 1685 Hz 
in males. They also observed that the input/output function of DPOAE differed between male 
smokers and male non-smokers as well as male smokers and female smokers, but this result was 
not statistically significant. Gopal et al. (2009) found that DPOAE amplitude was a significant 
predictor of measured CO levels. Specifically, the DPOAE for the left ear decreased with 
increases in CO levels. Rogha et al. (2015) showed a decrease in DPOAE amplitude at 1000, 
2000, 4000, and 6000 Hz in smokers compared with non-smokers, but found no significant 




 Further review of Table 7 shows that not only did the overall occurrence of TEOAE 
responses as well as presence per frequency band at 3000 – 4000 Hz differ significantly between 
smokers and non-smokers, but also the incidence of absent TEOAEs was higher in smokers then 
in non-smokers (Paschoal & Azevedo, 2009). Also, Lisowska et al. (2017) observed significantly 
lower levels of CEOAEs in male smokers compared with those in male non-smokers and in 
female smokers. But the difference in rates of present SOAEs between were male smokers and 





Smoke-Exposure and Outcome Measure, Procedures, and OAE Results 




Description of Outcome 
Measure  
Procedure Results 
Gopal et al (2009) 16 Qa and 
breath COb 
Breath CO levels PTTc (.25 - 8k Hz), pure 
tone average 500, 1000, and 
2000 Hz; ARTd measured 
ipsilaterally and 
contralaterally; ABRe 
latency and amplitude of 
wave V; TEOAEf measured 
at 1, 1.4, 2, 2.8, and 4k Hz; 
DPOAEg measured at 1, 1.4, 
2, 2.8, and 4k Hz; MLRh  
peak latency and amplitude 
of Na and Pa 
PTT performed in 
sound treated room; 
AEPi recorded to 
rarefaction clicks at 
intensity levels of 
40 - 80 dB nHL  
Right and left ear 
DPOAE**** variance 
accounted for in CO 
levels 
Lisowska et al 
(2017) 
84 Q Smoking status PTT and HFAj mean 
thresholds at each frequency, 
presence or absence of 
CEOAEk, SOAEl, and 
DPOAEm for non-smokers 
vs smokers, female smokers 
vs female non-smokers, 
male smokers vs male non-
smokers, female non-
smokers vs male non-
smokers, female smokers vs. 
male smokers 
PTT (.25k-8k Hz; 
HFA (8k-20kHz); 
sound treated room; 
CEOAE (present at 




(similar to CEOAE 
- unreported), 
DPOAE (SNR > 3 
dB) 
Overall CEOAE levels 
lower in male smokers 
compared to male non-
smokers and female 
smokers*, lower levels of 
DPOAE at f2=1685 Hz in 
male smokers*, I/O 
function of DPOAE 
differed between male 
smokers and male non-
smokers/female smokers- 
NSo, lower rates of SOAE 
in male smokers 
compared with male non-
smokers/female smokers 
- NS 
Negley et al 
(2007) 
24 Q Smoking status PTT - .25-8k Hz; HFA - 10-
20k Hz; DPOAE - 2-8k Hz 
PTT at 0.25-8kHz); 
HFA at 10-20kHz; 
Lower DPOAE 
amplitudes in smokers at 















moderate (65 and 50 dB 
SPL)** intensity levels 
Paschoal & 
Azevedo (2009) 
144 Q Smoking status Occurrence of tinnitus, PTT 
at .25 - 8k Hz, HFA at 
10000, 12500, 14000, and 
16000 Hz, TEOAE response, 







responses as well as 
responses at 3000 - 4000 
Hz in both ears sig. 
different in smokers**; 
higher incidence of 
absent TEOAE with 
normal hearing in 
smokers*; TEOAE 
suppression was also 
significantly different in 
both ears (medians of 3.2 
smokers, 2.5 non-
smokers)*** 
Prabhu et al  
(2017) 
50 Q Smoking status HFA thresholds at 8, 9, 
10.25, 12.5, and 16k Hz. 
DPOAE amplitude at 8, 9, 







Reduction in DPOAE 
amplitude, including 
HFOAEn* 
Rogha et al. 
(2015) 
32 Q Smoking status Mean thresholds at .25 - 16k 
Hz;  Abnormal results for 
DPOAE/TEOAE considered 
<6 at 1 000, 2000, 4000, and 
6000 Hz 
Pure tone testing 
using AC 40 
clinical audiometer; 
OAE performed 
using Eclipse EP25 
device 
Decreased in DPOAE 
amplitude at 1000, 2000, 
4000, and 6000 Hz in 




cPure Tone Threshold 
dAcoustic Reflex Threshold 
eAuditory Brainstem Response 
fTransient Evoked Otoacoustic Emissions 
gDistortion Product Otoacoustic Emissions 
hMiddle Latency Response 
iAuditory Evoked Potentials  
jHigh Frequency Audiometry 
kClick Evoked Otoacoustic Emissions 
l Spontaneous Otoacoustic Emissions 
mDistortion Product Otoacoustic Emissions 










Auditory Evoked Potentials  
Smoking effects on AEPs were examined in 6 (32%) of the 19 studies. Table 8 shows the 
outcome measures, procedures, and findings of the the studies on effects of smoking on AEPs. 
As seen from inspection of Table 8, significant, adverse effects of smoking on the AEPs 
occurred in all included studies (Gopal et al., 2009; Guney et al., 2009; Gupta et al., 2008; 
Jawinski et al., 2016; Mosbacher et al., 2009; Ramkissoon & Chambers, 2008;). Gopal et al. 
(2009), who examined the auditory brainstem responses (ABR), found that the ABR peak wave 
V amplitude at 80 dB nHL in both ears accounted for variance in CO levels. The negative 
correlation between wave V amplitude and CO level was seen only in the left ear. For the left 
ear, Gupta et al. (2008) found significantly prolonged mean latencies for I, III, and V and 
significantly prolonged III-V and I-V interpeak latencies in smokers with COPD as compared 
with healthy non-smokers. Similar findings were obtained for the right ear, except that no 
significant difference between groups was obtained for the mean wave I peak latency; the mean 
peak latency for wave IV was significantly prolonged for wave IV in the group of smokers with 
COPD as compared with the control group; and the I-III interpeak latency also was significantly 
prolonged in the smokers with COPD as compared with the control group. In both ears, the peak 
amplitudes for waves I and V in the smokers with COPD were significantly reduced as compared 
with those for the control group. Additionally, in the left ear, the peak latency for waves I and III 
significantly correlated negatively with Forced Expiratory Volume (FEV) (r = -.37 and r = -.33, 
respectively) and the peak amplitude of wave I significantly correlated negatively with smoking 
packs years (r = -.34). In the right ear, the peak amplitude of wave I correlated positively with 
the duration of COPD illness (r = .38); the investigators did not speculate on a possible 




abnormalities. Specifically, 60% presented with increased latencies of waves I – V and increased 
interpeak latencies of I – III, I – V, and III – V. A decrease in the amplitude of wave V – Va 
presented in 17.5% of patients and a decrease in wave I – Ia amplitude was noted in 12.5% of 
patients. 
As seen in Table 4, Ramkissoon and Chambers (2008) compared auditory middle latency 
responses (MLRs) in non-smokers as well as smokers in the “chronic” condition and the “acute” 
condition. Inspection of Table 8 reveals that they employed an objective measure of smoking 
status. Additionally, they controlled for age by having age be a factor with two levels (older vs. 
younger adults) in the MANOVA. Initially, for the chronic condition, smokers were tested at the 
point in the day in which they had smoked half their total daily consumption of cigarettes but had 
abstained from smoking two hours prior to testing. Smokers were then tested again immediately 
after smoking a cigarette of their usual brand; this represented the acute condition. The results of 
MANOVA revealed the absence of a significant effect on Na-Pa amplitude when chronic 
smokers were compared with non-smokers; additionally, the interaction of age and smoking was 
nonsignificant. For the acute condition, the MANOVA results also revealed significantly larger 
Na-Pa amplitudes in the acute than in the chronic condition, in both age groups. The authors 
speculated that this finding possibly reflected an excitatory effect of nicotine that is similar to the 
excitatory effect of acetylcholine in the subcortical regions of the primary auditory pathway 
(inferior colliculus and thalamus to the cortex) and in the secondary auditory pathways 
(projections from the reticular formation to the thalamus and cortex). These regions serve as 
generator sites for Na and Pa.  
As seen in Tables 4 and 8, Jawinkski et al. (2016) investigated N1-P2 amplitudes in those 




between ex-smokers and never smokers as well as current and never smokers, but not between 
ex- and current smokers. Individuals who had never smoked exhibited the highest N1-P2 
amplitudes followed by ex-smokers and finally current smokers. The steepest increase of N1-P2 
amplitudes across increasing presentation levels was found in those who had never smoked, 
followed by ex-smokers, and then by current smokers who demonstrated the shallowest increase. 
Packs per day and pack years was associated with reduced N1-P2 amplitudes at 72, 78, 84, and 
90 dB SPL in ex- smokers.  
Inspection of Table 8 further shows that two studies utilized the long-latency P300 to 
compare smokers with non-smokers (Guney et al., 2009; Mosbacher et al., 2009). Mobascher et 
al. found that those who never smoked had a higher P300 global field potential (GFP) than light 
smokers. Additionally, those who never smoked and light smokers had higher P300 GFPs than 
heavy smokers. The P300 current source density (CSD) was also reduced in smokers compared 
with those who never smoked, with heavy smokers having the lowest P300 CSD. In that study, 
the Fagerstrom test for nicotine dependence (FTND) was employed as the scale to represent an 
individual’s physical dependence on nicotine (Heatherton et al., 199991). Following age, the 
FTND was the second best predictive of P300 GFP. Guney et al. reported that at Fz, the P300 
and N1 amplitudes were reduced, and N1 latency was prolonged in smokers as compared with 







Smoke-Exposure and Outcome Measure, Procedures, and AEP Results 









Gopal et al 
(2009) 




PTTc (.25 - 8k 
Hz), pure tone 
average 500, 





ABRe latency and 
amplitude of 
wave V; TEOAEf 
measured at 1, 
1.4, 2, 2.8, and 4k 
Hz; DPOAEg 
measured at 1, 
1.4, 2, 2.8, and 4k 
Hz; MLRh peak 
latency and 
amplitude of Na 
and Pa 
PTT performed in sound treated 
room; AEPi recorded to 
rarefaction clicks at intensity 
levels of 40 - 80 dB nHL  
Right**** and left ear ABR 
peak V amplitude at 80 
dBnHL**, right ear ABR peak V 
amplitude at 40 dBnHL****  
were significant predictors of 
CO levels; these 5 predictors 
accounted for 75% of the 
variance in CO levels 
Guney et al 
(2009) 
64 Q Smoking 
status 






ERPj recordings in quiet room; 
oddball paradigm -2kHz target 
tone presented 20% of the time, 
1kHz non-target presented 80% 
of the time at 80 dB. Peak 
latencies measured at Cz and Fz 
P300 amplitude at Fz was lower 
in smokers than non-
smokers***; N1 amplitude at Fz 
was lower in smokers than in 
non-smokers**; N1 amplitude at 
Cz was lower in smokers than 
nonsmokers*; N1 latency at Fz 
was prolonged in smokers 















Gupta et al 
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wave I, II, III, IV, 
and V, interpeak 
latencies of I-III, 
I-V, and III-V, 
amplitude of 
waves I and V 
AEP recordings performed in 
sound-proof room with a click 
stimulus of 70 dB nHL at rate of 
11.1/s 
In both ears, COPD patients, 
prolonged wave I***; interpeak 
latencies of III-V and I-V 
prolonged in COPD patients vs. 
controls**; Amplitude of wave I 
and V were reduced in COPD 
patients***; 
LE: latencies of waves I, III, and 
V prolonged in COPD patients 
vs. controls***; latencies of 
waves II and IV also prolonged 
but were NS; wave III*** 
correlated negatively with FEVm; 
Amplitude of wave I correlated 
negatively with packs per years 
smoking* 
RE: latencies of waves III, IV, 
and V prolonged in COPD 
patients vs. controls***; 
interpeak latency of I-III were 
prolonged in the COPD 
group***; Amplitude of wave I 
correlated negatively with 
duration of illness** 
Jawinski et 
al (2016) 
1739 Q Smoking 
status 
N1 - P2 
amplitude at 72, 
78, 84, 90, and 96 
dB SPL as well 
as mean 
intensities, the 
linear slope, and 
the median slope 
N1-P2 amplitude at various 
intensities (linear and median 
slopes across intensities) in sound 
attenuated booth with insert 
earphones 450 pseudo-
randomized 1k Hz tones (30 ms 
duration, 10 ms rise/fall times) at 
5 calibrated intensities (72, 78, 
84, 90, 96 dB SPL) 
Never smokers exhibited highest 
N1-P2 amplitudes followed by 
ex-smokers and current 
smokers**; Significant 
difference between ex- and never 
smokers*, current and never 
smokers*, but not between ex- 
and current smokers; Steepest 















never smokers, ex- with 
intermediate phenotype, and 
current smokers showing 
shallowest increase*; Never 
smokers steeper increase in N1-
P2 amplitudes than ex-**; Packs 
per day and pack years 
associated with reduced N1-P2 
amplitudes at 72,78,84, and 90 
dB SPL in ex- smokers*; NSp 
dose effect for current smokers 
Mobascher 
et al (2009) 







P300 amplitude P300: oddball paradigm, 2kHz 
tone (target tone) presented 20% 
of the time, 1.5kHz tone (non-
target tone) presented 80% of the 
time. Right-hand button press to 
target tone 
NS effect of smoking status on 
P300 latency or reaction time.; 
Never smokers had higher P300 
GFPq than light smokers**; 
Never smokers and light 
smokers had higher P300 GFP 
than heavy smokers***; P300 
CSDr reduced in smokers 
compared to never smokers with 
heavy smokers having the lowest 
P300/P3b CSD;  FTND was the 
second most predictive regressor 


























of waves V, Pa, 
and Na, and 
relative 
amplitude of 
waves V-Na and 
Na-Pa on MLR 
Rarefaction click stimuli 
presented at 70 dBnHL. Testing 
was performed on smokers after 
they had smoked half of their 
daily cigarette consumption, but 
were asked to abstain two hours 
prior to testing representing the 
chronic condition, smokers were 
tested again immediately after 
smoking a cigarette of their usual 
brand, representing the acute 
condition 
When comparing non-smokers 
and chronic smokers , age 
accounted for 29% of the overall 
variance*; Na-PA amplitude was 
larger in acute compared to 
chronic smoking condition ***; 
Wave V latency was longer in 
older smokers compared to 
younger smokers*; NS for 
smoking behavior or interaction 
of smoking behavior and age 
aQuestionnaire  
bCarbon Monoxide 
cPure Tone Threshold 
dAcoustic Reflex Threshold 
eAuditory Brainstem Response 
fTransient Evoked Otoacoustic Emissions 
gDistortion Product Otoacoustic Emissions 
hMiddle Latency Response 
iAuditory Evoked Potentials  
jEvent Related Potentials 
kGlobal Initiative for Chronic Obstructive Lung 
Disease 
lChronic Obstructive Pulmonary Disease 
mForced Expiratory Volume 
nCarboxyhemoglobin 
oFagerstrom Test for Nicotine Dependence 
pNon-significant 
qGlobal Field Potential 










The purpose of this systematic review was to determine the effects of smoking on 
auditory function. Thus, studies examining a variety of outcome measures were included in the 
present systematic review. Significant findings were present across all outcome measures, 
including pure-tone thresholds, ultra high-frequency thresholds, OAEs, and AEPs, with the 
majority of studies controlling for age and other confounding factors including noise exposure 
and history of middle ear disorders.  
Significantly worse thresholds were obtained in smokers compared to non-smokers in 
both ears and across the conventional audiometric frequency range (.25 – 8k Hz) in the majority 
of studies regardless of participant age (Chang et al., 2016; Fabry et al., 2011; Kumar et al., 
2013; Negley et al., 2007; Oliveira & Lima, 2009; Prabhu et al., 2017; Sekher et al., 2017). Of 
note, a correlation was noted for those only exposed to secondhand smoke in the low – mid 
frequency range (.5 – 2k Hz) (Fabry et al.). Significant differences in pure-tone thresholds were 
also noted between those who never smoked and past smokers suggesting that the effects of 
cigarette smoke on the auditory system are long-lasting, regardless of smoking cessation (Chang 
et al.). Some discrepant findings were seen, however, as 3 studies did not obtain significant 
findings in this frequency region (Gopal et al., 2009; Ohgami et al., 2011; Ramkissoon & Cole, 
2011). Past smokers who had quit at least 3 years prior to testing were included in the non-
smoking group of one study in which results were non-significant (Ramkissoon & Cole). Perhaps 
the long-lasting effects of smoking previously mentioned contaminated these findings resulting 
in no significant differences between smokers and “non-smokers.” Gopal et al. only included 
those with no history of hearing loss and examined a small sample size (16). Both of which may 




in the conventional audiometric range, however, they did not examine the two lowest frequencies 
(.25 - .5 Hz) typically included in this range. 
The aforementioned effects of smoking generally observed on the conventional pure-tone 
thresholds persisted in the ultra-high frequency range with both significantly worse thresholds in 
smokers compared to non-smokers and a dose effect of decreasing thresholds with an increase in 
smoke exposure (Ohgami et al., 2011; Oliveira & Lima, 2009; Paschoal & Azevedo, 2009; 
Prabhu et al., 2017; Sumit et al., 2015). Effects in this frequency range, however, were more 
frequency specific with the majority of significant findings obtained at 12 – 14k Hz (Ohgami et 
al., 2011; Oliveira & Lima, 2009; Paschoal & Azevedo, 2009; Sumir et al., 2015). Two studies 
noted these effects across the ultra-high frequency range (9 – 16k Hz, and 9 – 20k Hz) (Lisowska 
et al., 2017; Prabhu et al.); in one of these two studies however, the findings trended towards 
significance but failed to reach significance. Two studies did not find significant differences in 
this range between smokers and non-smokers, however, they each had a small sample size 
(Negley et al., 2007; Rogha et al., 2015). 
Several subsets of OAEs were also measured and the results corroborate those noted for 
both the conventional pure-tone thresholds and ultra high-frequency thresholds. Decreases in the 
DPOAE and TEOAE amplitudes in the conventional frequency range were observed in smokers 
in several studies (Gopal et al., 2009; Lisowska et al., 2017; Negley et al., 2007; Paschoal & 
Azevedo, 2009; Prabhu et al., 2017; Rogha et al., 2015). In one study on DPOAEs in the ultra 
high-frequency range (9 – 16k Hz), amplitudes were significantly lower in smokers than non-
smokers (Prabhu et al., 2017).  
Significant effects of smoking were also found in AEP studies. Significant differences 




(Gopal et al., 2009; Guney et al., 2009; Gupta et al., 2008; Jawinski et al., 2016; Mobascher et 
al., 2009; Ramkissoon & Chambers, 2008). Both studies examining ABRs obtained significant 
findings, however, one of which only noted a correlation between CO levels and wave V (Gopal 
et al.). Gupta et al., on the other hand, found significant differences in several measures including 
absolute latencies, interwave latencies, and amplitudes, but these effects were noted in 
individuals with COPD, thus representing those most severely affected by smoke exposure. 
Additionally, several findings in this study were ear-specific (Gupta et al.). While many studies 
examining MLRs and smoking have been conducted, only one isolated the effects of cigarette 
smoke and excluded those with psychological disgnoses. Significant findings, however, were 
achieved (Ramkissoon & Chambers). In contrast to the negative correlations found, Ramkissoon 
and Chambers observed a significantly larger Na-Pa amplitude in the acute than in the chronic 
smoking condition. Those investigators speculated this finding illustrates the arousal effects of 
nicotine that may be attributed to increase neural synchronization which presents as an excitatory 
response, or in this study, larger Na-Pa responses.  
In the remaining AEP studies, significant smoking effects were obtained on the long 
latency potentials, specifically, N1-P2 and P300 (Guney et al., 2009; Jawinski et al., 2016; 
Mobascher et al., 2009). Significantly lower N1-P2 amplitudes were noted in smokers compared 
to non-smokers in the two studies which examined this measure (Guney et al.; Jawinski et al.). 
One of these studies also noted significantly prolonged N1 latency in smokers when compared to 
non-smokers. Similarly to N1-P2, of the two studies examining P300, both achieved significant 
results. Specifically reduced P300 responses were noted in smokers compared to those who had 





A dose effect, illustrated in several different ways, was noted across outcome measures. 
In regards to pure tone thresholds, the effect was noted in smokers in several studies with 
thresholds increasing as smoke exposure, quantified as years smoking as well as packs per day, 
increased (Kumar et al.; Prabhu et al.; Sumit et al., 2015). Similar to that of pure tone thresholds, 
in one study, the amplitude of wave I in the right ear correlated negatively with duration of 
illness, and the right ear, and amplitude of wave I in the left ear correlating negatively with packs 
per years smoking (Gupta et al., 2008). 
Supporting the idea of a dose effect, studies which examined either past smokers or those 
exposed to SHS found significant differences between the aforementioned groups and those with 
no smoke exposure at all, as well as significant differences between those groups and current 
smokers. Significant differences in pure-tone thresholds were also noted between those who 
never smoked and past smokers suggesting that the effects of cigarette smoke on the auditory 
system are long-lasting, regardless of smoking cessation (Chang et al.). This effect was also 
noted in studies examined AEPs as an outcome measure. Jawinski et al. found significantly 
higher N1-P2 amplitudes in persons who never smoked followed by ex-smokers with the next 
highest amplitude, and current smokers with the lowest N1-P2 amplitude. Although significant 
differences between never smokers and current smokers, as well as never smokers and ex-
smokers were noted, no significant difference was noted between ex-smokers and current 
smokers. Participants, however, in the ex-smoking group had quit smoking a minimum of 12 
months prior to this study. Perhaps if ex-smokers had quit far longer prior to this study, 
significant differences would have been achieved between these two groups. As mentioned 
previously, despite smoking cessation, perhaps long term effects of smoking persist, thus 




Supporting such, a significant dose effect was seen (N1-P2 amplitude inversely related to packs 
per day and pack years) in ex- smokers (Jawinski et al., 2016). Effects were noted in P300 
amplitude as well with persons who never smoked having significantly higher P300 GFP than 
light smokers and similarly, persons who never smoked and light smokers had higher P300 GFP 
than heavy smokers (Mobascher et al., 2009). 
While a comparison can only be made in terms of conventional pure tone thresholds, as 
the past review only included such, the present systematic review corroborates the 
aforementioned meta-analysis, with positive correlations found in the majority of included 
studies (Nomura, Nakao, and Morimoto, 2005). Furthermore, caution should be taken when 
comparing the two reviews for several reasons. Nomura, Nakao, and Morimoto did not include 
studies involving passive smokers and included those exposed to noise, in contrast to the present 
review. Additionally, a vast majority of studies in the Nomura, Nakao and Morimoto review did 
not adjust for age related differences. It should also be noted that subjects in studies published 
after the meta-analysis, and those included in this review, were excluded if they had a history of 
noise exposure whereas subjects with noise exposure histories were included in the studies 
evaluated by Nomura, Nakao, and Morimoto. Statistical analyses, however, were performed to 
adjust for noise exposure (Nomura, Nakao, & Morimoto). 
The majority of studies (17 of 19) controlled for age in some capacity, whether it be only 
including younger participants, delineating “younger” and “older” groups, statistically adjusting 
for age, or age-matching control groups. Many, (15 of 19) however, did not adjust for gender nor 
compare the results of male and female smokers and non-smokers. One study examining OAEs, 
conventional pure tone thresholds, and ultra high frequency thresholds, found significant 




justifying the need for future research considering such (Lisowska et al., 2017). Very few studies 
(3 of 19) included passive smokers and/or ex-smokers. As a dose effect was noted in several 
studies across outcome measures when comparing passive smokers, ex-smokers, current 
smokers, and non-smokers, future research delineating such groups is needed. Only 6 studies 
utilized any form of auditory evoked potential, with 2 examining ABRs, 1 examining MLR and 
the remaining 3 examining long latency potentials such as N1-P2 and/or P300. While significant 
differences between smokers and non-smokers were achieved, future research is needed to 
corroborate these findings. Additionally, one study examining ABRs obtained ear specific 
significant differences between smokers and non-smokers (Gupta et al., 2008). Thus, future 
research is needed to repeat the study with a larger sample size to see if these findings would 














The adverse effects of cigarette smoke on auditory function are present and clear 
throughout the literature reviewed. As a result, smoking behavior should be avoided due to its 
effects on auditory function, as well as the myriad of other heavily researched deleterious side 
effects. Specific to the effects on auditory function, it would be advantageous to include a 
question of smoking behavior in an audiologic evaluation intake form. This question should also 
probe systematic exposure to secondhand smoke due to the effects of passive smoking. 
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